Matching articles for "Zohydro"
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Comparison Table: Some Oral/Topical Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
...
View the Comparison Table: Some Oral/Topical Opioid Analgesics
Abuse-Deterrent Opioids
The Medical Letter on Drugs and Therapeutics • June 5, 2017; (Issue 1522)
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this subject, several new abuse-deterrent opioid
formulations have been approved by the FDA,
including an oxycodone tablet formulation (Roxybond
– Inspirion) that is the first immediate-release opioid
product FDA-approved to include claims of abuse
deterrence in its labeling. No opioid formulation
prevents consumption of a large number of intact
dosage units, the most common method of abuse.
Abuse-deterrent formulations have one or more
properties that make their intentional nontherapeutic
use more difficult, less attractive, or less rewarding.
Arymo ER - A New Abuse-Deterrent Morphine Formulation
The Medical Letter on Drugs and Therapeutics • April 24, 2017; (Issue 1519)
The FDA has approved Arymo ER (Egalet), a new
extended-release, abuse-deterrent tablet formulation
of morphine sulfate, for management of pain severe
enough to require daily, around-the-clock,...
The FDA has approved Arymo ER (Egalet), a new
extended-release, abuse-deterrent tablet formulation
of morphine sulfate, for management of pain severe
enough to require daily, around-the-clock, long-term
opioid treatment and for which alternative treatment
options are inadequate. Arymo ER can only be
marketed to deter abuse by injection because another
single-entity, extended-release morphine product,
MorphaBond, which has not been marketed to date,
has marketing exclusivity for deterrence of abuse by
the intranasal route through October 2018.
A New Abuse-Deterrent Opioid - Xtampza ER
The Medical Letter on Drugs and Therapeutics • June 20, 2016; (Issue 1497)
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term...
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative
treatment options are inadequate.
Abuse-Deterrent Opioid Formulations
The Medical Letter on Drugs and Therapeutics • August 31, 2015; (Issue 1476)
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and public
health advocates. Three available opioid...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and public
health advocates. Three available opioid formulations,
OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER
(Purdue), now include claims of abuse deterrence in
their package inserts.
Extended-Release Hydrocodone (Zohydro ER) for Pain
The Medical Letter on Drugs and Therapeutics • June 9, 2014; (Issue 1444)
The FDA has approved an extended-release oral formulation
of the opioid agonist hydrocodone (Zohydro ER –
Zogenix) for management of pain severe enough to
require continuous, long-term therapy and for...
The FDA has approved an extended-release oral formulation
of the opioid agonist hydrocodone (Zohydro ER –
Zogenix) for management of pain severe enough to
require continuous, long-term therapy and for which
alternative treatment options are inadequate. Zohydro ER
is the first single-ingredient hydrocodone product to be
marketed in the US. Hydrocodone has been available for
years in combination with acetaminophen (Vicodin, and
others) or ibuprofen (Vicoprofen, and others).